103195-35-3

Basic information

• Product Name: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate
• Synonyms: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate;8-Amino-4-oxo-4H-1-benzopyran-2-carboxylic acid ethyl ester;ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate(WXG00429)
• CAS NO: 103195-35-3
• Molecular Formula: C₁₂H₁₁NO₄
• Molecular Weight: 233.22004
• Mol File: 103195-35-3.mol

Chemical Properties

• Appearance: /
• Density: 1.359
• CAS DataBase Reference: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate(103195-35-3)
• EPA Substance Registry System: ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate(103195-35-3)

Safety Data

• Hazardous Substances Data: 103195-35-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate serves as a key intermediate in the synthesis of various drugs. Its unique structure and pharmacological properties make it a valuable compound for the development of new medications.
Used in Medical Research:
Due to its anti-inflammatory, antioxidant, and anticancer activities, ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate is used as a subject of study in medical research. Scientists explore its potential applications in treating various diseases and conditions, as well as its mechanisms of action.
Used in Agriculture:
Ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate may have potential applications in agriculture, possibly as a component in the development of new pesticides or as a means to enhance crop yields and resistance to diseases.
Used in Industrial Chemistry:
ethyl 8-aMino-4-oxo-4H-chroMene-2-carboxylate could be utilized in industrial chemistry for various purposes, such as the synthesis of specialty chemicals, dyes, or other products that require its unique structural and functional attributes.
Used in Material Science:
Ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate may also find applications in material science, where its properties could be harnessed to develop new materials with specific characteristics, such as improved stability, reactivity, or other desirable traits.

Upstream product

• 110683-75-5 ethyl 8-nitro-4-oxo-4H-benzopyran-2-carboxylate 
• 161369-33-1 8-nitro-2-methoxycarbonyl-4-oxo-4H-1-benzopyran 
• 182356-63-4 (Z)-2-Hydroxy-4-(2-hydroxy-3-nitro-phenyl)-4-oxo-but-2-enoic acid ethyl ester 
• 28177-69-7 2-hydroxy-3-nitroacetophenone 

Downstream Products

• 136450-08-3 ethyl 4-oxo-8-(4-(4-phenylbutoxy)benzamido)chromene-2-carboxylate 
• 136450-09-4 8-[4-(4-phenylbutoxy)benzoyl]amino-2-methoxycarbonyl-4-oxo-4H-1-benzopyran 
• 1443367-04-1 8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid 
• 1443367-31-4 4-oxo-8-(4-propoxybenzamido)-4H-chromene-2-carboxylic acid 
• 1443367-27-8 ethyl 4-oxo-8-(4-propoxybenzamido)-4H-chromene-2-carboxylate 
• 1443367-30-3 8-(4-(cyclopropylmethoxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 
• 1443366-70-8 ethyl 8-(4-bromobenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443366-69-5 ethyl 8-(4-Methoxybenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443366-68-4 ethyl 4-oxo-8-(4-(trifluoromethyl)benzamido)-4H-chromene-2-carboxylate 
• 1443366-67-3 ethyl 8-(4-methylbenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443366-66-2 ethyl 8-(3-nitrobenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443366-65-1 ethyl 8-(3-methylbenzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1258763-55-1 ethyl 8-benzamido-4-oxo-4H-chromene-2-carboxylate 
• 1443366-59-3 ethyl 4-oxo-8-(2-phenylacetamido)-4H-chromene-2-carboxylate 

Relevant articles and documents

Malonic acid receptors with decarboxylative activity

The geometry and electronic properties of several malonic acids receptors are studied with a view to optimizing their decarboxylative activity.

Development and application of a high-throughput screening assay for identification of small molecule inhibitors of the P. falciparum reticulocyte binding-like homologue 5 protein

The P. falciparum parasite, responsible for the disease in humans known as malaria, must invade erythrocytes to provide an environment for self-replication and survival. For invasion to occur, the parasite must engage several ligands on the host erythrocyte surface to enable adhesion, tight junction formation and entry. Critical interactions include binding of erythrocyte binding-like ligands and reticulocyte binding-like homologues (Rhs) to the surface of the host erythrocyte. The reticulocyte binding-like homologue 5 (Rh5) is the only member of this family that is essential for invasion and it binds to the basigin host receptor. The essential nature of Rh5 makes it an important vaccine target, however to date, Rh5 has not been targeted by small molecule intervention. Here, we describe the development of a high-throughput screening assay to identify small molecules which interfere with the Rh5-basigin interaction. To validate the utility of this assay we screened a known drug library and the Medicines for Malaria Box and demonstrated the reproducibility and robustness of the assay for high-throughput screening purposes. The screen of the known drug library identified the known leukotriene antagonist, pranlukast. We used pranlukast as a model inhibitor in a post screening evaluation cascade. We procured and synthesised analogues of pranlukast to assist in the hit confirmation process and show which structural moieties of pranlukast attenuate the Rh5 – basigin interaction. Evaluation of pranlukast analogues against P. falciparum in a viability assay and a schizont rupture assay show the parasite activity was not consistent with the biochemical inhibition of Rh5, questioning the developability of pranlukast as an antimalarial. The high-throughput assay developed from this work has the capacity to screen large collections of small molecules to discover inhibitors of P. falciparum Rh5 for future development of invasion inhibitory antimalarials.

Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators

Selective optimization of side activities (SOSA) offers an alternative entry to early drug discovery and may provide rapid access to bioactive new chemical entities with desirable properties. SOSA aims to reverse a drug's side activities through structural modification and to design out the drug's original main action. We identified a moderate side activity for the cysteinyl leukotriene receptor 1 (CysLT1R) antagonist pranlukast on the farnesoid X receptor (FXR). Systematic structural modification of the drug allowed remarkable optimization of its partial FXR agonism to sub-nanonmolar potency. The resulting FXR modulators lack any activity on CysLT1R and are characterized by high selectivity, high metabolic stability, and low toxicity. With their favorable in vitro profile, these SOSA-derived FXR modulators constitute a new FXR ligand chemotype that appears suitable for further preclinical evaluation.

8-benzamidochromen-4-one-2-carboxylic acids: Potent and selective agonists for the orphan G protein-coupled receptor GPR35

8-Amido-chromen-4-one-2-carboxylic acid derivatives were identified as novel agonists at the G protein-coupled orphan receptor GPR35. They were characterized by a β-arrestin recruitment assay and optimized to obtain agonists with nanomolar potency for the

PROCESS FOR PRODUCING CHROMONE COMPOUND

A process for producing a dicarboxylic acid compound represented by the formula (4): wherein R1 and R2 are the same or different and each represents lower alkyl and the wavy line indicates that this compound is the E- or Z-isomer or

Chromenone Derivatives as Receptors for N-Benzoylamino Acids

The chromenone derivative 5, easy to synthesize from 2-hydroxyacetophenone 1, has been used to prepare the host 7-10 and 12.These combine three hydrogen bonds, ?-stacking and charge-transfer interactions for the complexation of N-benzoylamino acids in CDC

New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships

(p-Amylcinnamoyl)anthranilic acid (3a) had moderate antagonist activities against LTD4-induced smooth muscle contraction on guinea pig ileum and LTC4-induced bronchoconstriction in anesthetized guinea pigs. Modifications were made in the hydrophobic part (cinnamoyl moiety) and the hydrophilic part (anthranilate moiety) of 3a. A series of 8-(benzoylamino)-2-tetrazol-5-yl-1,4-benzodioxans and 8-(benzoylamino)-2-tetrazol-5-yl-4-oxo-4H-1-benzopyrans were revealed to be potent antagonists of leukotrienes C4 and D4. Among both series, ONO-RS-347 (18k) and ONO-RS411 (19h) were the most potent and orally active antagonists, respectively. Structure-activity relationships are discussed.